Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep;33(3):681-692.
doi: 10.1016/j.idc.2019.05.003. Epub 2019 Jun 22.

Initial Antiretroviral Therapy in an Integrase Inhibitor Era: Can We Do Better?

Sean G Kelly  1 , Mary Clare Masters  2 , Babafemi O Taiwo  2
Affiliations
Review

Initial Antiretroviral Therapy in an Integrase Inhibitor Era: Can We Do Better?

Sean G Kelly et al. Infect Dis Clin North Am. 2019 Sep.

Abstract

With the second-generation integrase inhibitors (dolutegravir and bictegravir) extending the attributes of earlier integrase inhibitors, three-drug regimens containing integrase inhibitors plus two nucleos(t)ide reverse transcriptase inhibitors are now widely recommended for first-line (initial) treatment of human immunodeficiency virus-1 infection. Led by dolutegravir plus lamivudine, two-drug therapy is emerging as a way to reduce antiretroviral therapy cost and adverse effects without compromising treatment options should virologic failure occur. Initial two-drug therapy has limitations, including the relative incompatibility with the coemerging concept of same-day antiretroviral therapy initiation.

Keywords: Bictegravir; Dolutegravir; Dual therapy; Integrase stand transfer inhibitors; Rapid start.

PubMed Disclaimer

Conflict of interest statement

Disclosure Statement: B.O. Taiwo has served as a consultant for ViiV, GSK, Gilead, Merck, and Janssen; and received research funding through Northwestern University from ViiV. S.G. Kelly and M.C. Masters have no potential conflicts of interest.

References

    1. Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis cariniipneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med 1981;305(24):1425–31. - PubMed
    1. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220(4599):868–71. - PubMed
    1. Dalgleish AG, Beverley PC, Clapham PR, et al. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984;312(5996): 763–7. - PubMed
    1. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987;317(4):185–91. - PubMed
    1. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Available at: https://aidsinfo.nih.gov/guidelines/html/1Zadult-and-adolescent-arv/0. Accessed September 13, 2018.

Publication types

MeSH terms

Substances